Skip to main content
main-content

The independent medical news service

Kidney cancer

19-01-2022 | Oncology | News | Article

CheckMate 9ER HRQoL data support first-line nivolumab–cabozantinib in advanced RCC

People receiving nivolumab plus cabozantinib for advanced renal cell carcinoma report less decline in health-related quality of life during treatment than those given sunitinib, show data from the phase 3 CheckMate 9ER trial.

18-01-2022 | Oncology | News | Article

Reassurance on radiotherapy use prior to ICI initiation

Treatment with immune checkpoint inhibitors within 90 days of radiotherapy does not lead to a “meaningful increase” in rates of serious adverse events, say researchers who conducted a pooled analysis of US FDA registry data.

23-12-2021 | Oncology | News | Article

EMA issues positive GU cancer opinions

Read more about the urothelial cancer and renal cell carcinoma decisions here

16-12-2021 | Oncology | News | Article

HLA-A*03 shows potential as a biomarker for ICI response

The risk for disease progression or death increases with HLA-A*03 allele count in people undergoing immune checkpoint inhibitor therapy for cancer, irrespective of tumor type and agent used, research suggests.

02-11-2021 | Oncology | News | Article

Radiotherapy without systemic therapy feasible for oligometastatic RCC

Definitive radiotherapy without systemic therapy may be a feasible strategy for the treatment of oligometastatic renal cell carcinoma, phase 2 study findings indicate.

21-10-2021 | Oncology | News | Article

Cabozantinib shows activity against RCC brain metastases

Cabozantinib has “considerable” intracranial activity in patients with advanced renal cell carcinoma and brain metastases, say the authors of a chart review published in JAMA Oncology.

19-10-2021 | Oncology | News | Article

EMA gives green light for first-line use of lenvatinib plus pembrolizumab in advanced RCC

Click through for the details of this positive opinion

18-10-2021 | Oncology | News | Article

PARP1 may predict ICI response in patients with advanced RCC

PARP1 could help identify patients with advanced clear cell renal cell carcinoma who are likely to benefit from immune checkpoint inhibitor treatment, with particular utility in those with PBRM1-mutated disease, indicate findings.

21-09-2021 | Oncology | News | Article

Drug-free interval feasible in metastatic RCC

Incorporating a drug-free interval into first-line treatment for metastatic clear cell renal cell carcinoma may not be detrimental to patient survival or quality of life, suggest STAR trial data presented at the ESMO Congress 2021.

17-08-2021 | Oncology | News | Article

FDA approves HIF-2α inhibitor belzutifan for VHL-associated tumors

Read more on this US FDA announcement here

16-08-2021 | Oncology | News | Article

Lenvatinib–pembrolizumab gets FDA nod for first-line advanced RCC

Click through for the details of this decision

16-07-2021 | Oncology | News | Article

Ex vivo tumor platform gives window to PD-1 blockade response

A patient-derived tumor fragment platform has allowed close examination of the early immunologic responses to PD-1 blockade, revealing a relationship between immune cell reactivation and clinical response.

21-06-2021 | Oncology | News | Article

Bacterial product linked to improved metastatic RCC response to nivolumab plus ipilimumab

Preliminary research presented at the 2021 ASCO Annual Meeting suggests that use of a bacterial product might improve response to checkpoint inhibitor therapy in patients with metastatic renal cell carcinoma.

09-06-2021 | Oncology | News | Article

HRQoL data favor lenvatinib–pembrolizumab over sunitinib in advanced RCC

Patients who receive lenvatinib plus pembrolizumab for advanced renal cell carcinoma report similar or better health-related quality of life than those who receive sunitinib, show data from the phase 3 CLEAR trial.

07-06-2021 | Oncology | News | Article

CANTATA: No improvement in advanced RCC outcomes with telaglenastat addition

The combination of telaglenastat and cabozantinib offers no extra benefit over cabozantinib alone in the second- or third-line treatment of advanced clear cell renal cell carcinoma, suggest phase 2 trial results.

04-06-2021 | Oncology | News | Article

KEYNOTE-564 supports adjuvant pembrolizumab use in high-risk RCC patients

Postoperative treatment with pembrolizumab significantly improves the disease-free survival of patients with high-risk, clear cell renal cell carcinoma relative to placebo, show trial data.

26-05-2021 | Oncology | News | Article

First-line immunotherapy benefits transfer to real-world clear cell RCC

Real-world study data show that first-line immunotherapy alone or in combination with targeted therapy is associated with better overall survival than targeted therapy alone in people with metastatic clear cell renal cell carcinoma.

23-04-2021 | Oncology | News | Article

Lenvatinib–everolimus has ‘encouraging activity’ in untreated non-clear cell RCC

Previously untreated patients with advanced non-clear cell renal cell carcinoma could benefit from treatment with lenvatinib plus everolimus, suggests a phase 2 study.

16-04-2021 | Oncology | News | Article

Outliers in link between obesity and poor cancer survival reinforced in meta-analysis

Individuals with obesity tend to have worse cancer survival outcomes than those without obesity, unless they have lung cancer, renal cell carcinoma, or melanoma, show findings of a systematic review and meta-analysis.

07-04-2021 | Oncology | News | Article

Evidence for active surveillance in mRCC grows

Real-world data suggest that active surveillance may be a feasible treatment option for some patients with metastatic renal cell carcinoma.

Image Credits